RF-4,309
Revision as of 19:35, 23 March 2022 by Protondonor (talk | contribs) (Created page with "'''RF-4,309''' is an investigational drug that may potentially treat metaplastic carcinoma. It is natural product based on a peptide found in the cocoon of the native Lohetan fox moth. It was developed by a joint research team between Loheta and Goal and is under patent by Yexmuireuikil-based biotech company RǎoFùgnìn. Due to breakdown in the stomach, it must be administered via injection or infusion, and has shown the potential for highly toxic si...")
RF-4,309 is an investigational drug that may potentially treat metaplastic carcinoma. It is natural product based on a peptide found in the cocoon of the native Lohetan fox moth. It was developed by a joint research team between Loheta and Goal and is under patent by Yexmuireuikil-based biotech company RǎoFùgnìn. Due to breakdown in the stomach, it must be administered via injection or infusion, and has shown the potential for highly toxic side effects in animal studies. Phase 1 clinical trials are slated to start in 2023.